Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

11.24 +0.04 (+0.36%)
Streaming Delayed Price Updated: 3:05 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Emergent Biosolutions

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate
Emergent BioSolutions Inc (NYSE: EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and... 
Via Benzinga
Exposures COVID-19
Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns
More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment
Emergent BioSolutions Inc (NYSE: EBS) has announced the initiation of a Phase 3 trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous... 
Via Benzinga
Exposures COVID-19
Emergent BioSolutions inc (EBS) Q2 2021 Earnings Call Transcript
EBS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant
Emergent BioSolutions Inc (NYSE: EBS) will resume production of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine at its troubled Baltimore... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
These Companies Have Seen Large Returns From 2020 Government Investment
Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal... 
Via Benzinga
FDA Releases More JNJ's COVID-19 Vaccine Substance From Baltimore Plant
Federal regulators on Friday 
Via Benzinga
Exposures COVID-19 Product Safety
Can Emergent BioSolutions Recover From Its Recent Blunders?
Yes, but it probably won't be an easy path. 
Via The Motley Fool
Exposures COVID-19
Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
Moderna Inc (NASDAQ: MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine. The COVID-... 
Via Benzinga
Exposures COVID-19
A Look Into Healthcare Sector Value Stocks
What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
FDA Authorizes 10M JNJ COVID-19 Vaccine Doses, Asks To Discard 60M From Emergent Plant: NYT
The FDA has asked Johnson & Johnson (NYSE: JNJ) to discard 60 million doses of its COVID-19 vaccine manufactured at the troubled Emergent BioSolutions Inc... 
Via Benzinga
Exposures COVID-19 Product Safety
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (... 
Via Benzinga
Exposures COVID-19
Emergent BioSolutions Poised To Receive FDA Nod to Restart J&J COVID-19 Shot Production at Baltimore Plant After Mishap: WSJ
The FDA and Johnson & Johnson (NYSE: JNJ) are expected to announce that contamination problems at Emergent BioSolutions Inc’s (NYSE: EBS) Baltimore... 
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Iterum Therapeutics (NASDAQ:ITRM) shares moved upwards by 21.13% to $1.49 during Friday's pre-market session. The company's market cap stands at $266.9... 
Via Benzinga
Justice Department Opens Probe In Presumed lapses at Eli Lilly's COVID-19 Drug Plant: Reuters
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (NYSE: LLY) focused on alleged manufacturing irregularities and records... 
Via Benzinga
Exposures COVID-19
Emergent BioSolutions's Single-Dose Chikungunya Vaccine Candidate Effective Even After Two Years of Vaccination
Emergent BioSolutions Inc (NYSE: EBS) has announced two-year persistence data from its Phase 2 study evaluating its investigational chikungunya virus, virus-like... 
Via Benzinga
Emergent BioSolutions Stock Falls As Executives Face Questions As Part Of Botched Vaccine Probe
The House Select Subcommittee on the Coronavirus announced last month that they were opening an investigation into Emergent BioSolutions Inc (NYSE: EBS), with... 
Via Benzinga
Exposures COVID-19
Cramer Weighs In On Beyond Meat, Snowflake, More
Jim Cramer said on CNBC's "Mad Money Lightning Round" he would buy more shares of Anthem Inc (NYSE: ANTM). He also likes UnitedHealth Group Inc (NYSE: UNH) and... 
Via Benzinga
Emergent Initiates Quality Enhancement Plan For Troubled Baltimore Vaccine Facility
Emergent BioSolutions Inc (NYSE: EBS) has been in headlines after its Baltimore plant has drawn the scrutiny of the FDA. A manufacturing mix-up ruined 15 million... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2021
Upgrades Atlantic Equities upgraded the previous rating for Under Armour Inc (NYSE:UAA) from Underweight to Neutral. Under Armour earned $0.16 in the first quarter. The... 
Via Benzinga
Why Emergent BioSolutions Stock Dropped 30% in April
The company went from hero to zero in the fight against COVID-19. 
Via The Motley Fool
Exposures COVID-19
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.